Albert Lo

University of Pennsylvania — United States

Medicine · Health Sciences

20h-index4.9kcitations27works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), Peptidase Inhibition and Analysis(7), Immune Cell Function and Interaction(5), Monoclonal and Polyclonal Antibodies Research(4), Immunotherapy and Immune Responses(3)

Publications27 total

Author Correction: Targeting cardiac fibrosis with engineered T cells
Nature·2019· 6 citedOpen Access
Targeting cardiac fibrosis with engineered T cells
Nature·2019· 753 citedOpen Access
CRISPR-mediated live imaging of genome editing and transcription
Science·2019· 296 cited
Temporal-Spatial Visualization of Endogenous Chromosome Rearrangements in Living Cells
2019· 2 citedOpen Access
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
OncoImmunology·2017· 159 citedOpen Access
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors
Cancer Cell·2017· 626 citedOpen Access
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma
JCI Insight·2017· 155 citedOpen Access
Genetic and epigenetic control of gene expression by CRISPR–Cas systems
F1000Research·2017· 78 citedOpen Access
Abstract B27: Blockade of protein kinase A (PKA) localization augments the trafficking and anti-tumor efficacy of adoptively transferred chimeric antigen receptor-expressing T cells
Cancer Research·2016
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Cancer Immunology Research·2016· 184 citedOpen Access
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Cancer Immunology Research·2016· 121 citedOpen Access
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Cancer Research·2016· 504 citedOpen Access
Finding Common Ground to Treat Primary and Metastatic Cancer: The Potential of Targeting Tumor Stroma
ScholarlyCommons (University of Pennsylvania)·2016Open Access
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Clinical Cancer Research·2015· 120 citedOpen Access
Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia
Cancer Research·2015
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Cancer Research·2015· 478 cited
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Cancer Immunology Research·2015· 111 citedOpen Access
Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer
American Journal Of Pathology·2015· 108 citedOpen Access
Treatment of Aldosterone-Secreting Adrenocortical Tumors in Cats by Unilateral Adrenalectomy: 10 Cases (2002–2012)
Journal of Veterinary Internal Medicine·2013· 44 citedOpen Access
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Cancer Immunology Research·2013· 619 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ellen Puré(14), Steven Μ. Albelda(10), Carl H. June(8), John Scholler(6), Kheng Newick(6), James Monslow(5), Liang‐Chuan S. Wang(5), Edmund K. Moon(5), Shaun O’Brien(4), Han‐Chung Wu(4), Robert H. Vonderheide(3), Veena Kapoor(3), Amy C. Durham(3), Diana Avery(3), Elizabeth L. Buza(3), Lei S. Qi(3), Haig Aghajanian(2), Tōru Kimura(2), Joel G. Rurik(2), Aidan S. Hancock(2)